PT-141

Overview

PT-141 (bremelanotide) is a synthetic peptide that selectively activates the melanocortin-4 receptor (MC4R), part of the melanocortin receptor family found in the brain, and is chemically related to (though a distinct research subject from) the other melanocortin compounds in this index.

Proposed Mechanism

Activates melanocortin-4 receptors in the hypothalamus, a central pathway distinct from vascular-mechanism sexual health compounds.

Research Context

Research on PT-141 has focused on sexual arousal and desire through a central-nervous-system mechanism, which distinguishes it from other approaches to sexual health that work through vascular mechanisms (affecting blood flow) rather than through the brain's own arousal-signalling pathways.

Evidence Status — Well-documented

The only melanocortin compound in this library with full regulatory approval (as Vyleesi) for a defined indication.

PT-141 is the only melanocortin compound in this index to have received full regulatory approval as a specific pharmaceutical product (marketed as Vyleesi) for a defined indication. That approval applies to that specific approved product, not to research-grade bremelanotide generally.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.